{"id":536233,"date":"2021-09-09T08:03:55","date_gmt":"2021-09-09T12:03:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-09T08:03:55","modified_gmt":"2021-09-09T12:03:55","slug":"entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright <em>23<\/em><sup><em>rd<\/em><\/sup><em> Annual Global Investment Conference<\/em>. Details of the Company\u2019s participation are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Conference: <em>H.C. Wainwright 23<\/em><sup><em>rd<\/em><\/sup><em> Annual Global Investment Conference<\/em><\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Dates: September 13-15, 2021<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Format:<\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%;text-align: left;vertical-align: middle;vertical-align: top\">Fireside chat available on-demand beginning September 13<sup>th<\/sup> at 7:00am ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">One-on-one investor meetings<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Entasis<br \/><\/strong>Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting <em>Acinetobacter baumannii<\/em> infections), zoliflodacin (targeting <em>Neisseria gonorrhoeae<\/em> infections), ETX0462 (targeting multiple Gram-negative pathogens including <em>Pseudomonas aeruginosa<\/em>) and ETX0282CPDP (targeting <em>Enterobacteriaceae<\/em> infections). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0KxiaBu3uLVn_-tC8Q1l7ClgSFX9Nn54tyoj7RgWkMqFyYNox-DkKJmN4hlEiJ0MmOuAomXKzP1ICR3buMkJew==\" rel=\"nofollow noopener\" target=\"_blank\">www.entasistx.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Entasis Contacts <\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><strong>Company:<\/strong><br \/>Kyle Dow <br \/>Entasis Therapeutics <br \/>(781) 810-0114 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gNEtSrEhvNrdor4Tt4Z-0sBGJC8rq3chDhgn5lpTWebakRNLJyZ0EjI5TcgC9Y4oXzpB0ZoVCeGtOV4ntImWP3m6RTg_IsiTopn6lhcVLs4=\" rel=\"nofollow noopener\" target=\"_blank\">kyle.dow@entasistx.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>LifeSci Advisors<br \/>(929) 469-3859<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f2lz7S6LVUrhHA6_bO0BjUrmhdAYLyeWnzGISPLdk1nS_qZ6jNFqJ-BNq-lz1n-JEu7Q8vCpGXpBdNtClyaKm6SxHvcDJezbjaF6pfxk6J7Ta_7CLsMxclM5V4g0IsEr\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzM0NmVhMGItNDI0ZS00ODZmLTgxZDItZWQzYTE3NGI2YjhlLTExMDc0MjQ=\/tiny\/Entasis-Therapeutics-Holdings-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company\u2019s participation are as follows: Conference: H.C. Wainwright 23rd Annual Global Investment Conference Dates: September 13-15, 2021 Format: Fireside chat available on-demand beginning September 13th at 7:00am ET \u00a0 One-on-one investor meetings About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536233","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company\u2019s participation are as follows: Conference: H.C. Wainwright 23rd Annual Global Investment Conference Dates: September 13-15, 2021 Format: Fireside chat available on-demand beginning September 13th at 7:00am ET \u00a0 One-on-one investor meetings About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting &hellip; Continue reading &quot;Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-09T12:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":184,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=\",\"datePublished\":\"2021-09-09T12:03:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company\u2019s participation are as follows: Conference: H.C. Wainwright 23rd Annual Global Investment Conference Dates: September 13-15, 2021 Format: Fireside chat available on-demand beginning September 13th at 7:00am ET \u00a0 One-on-one investor meetings About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting &hellip; Continue reading \"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:03:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-09T12:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":184,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=","datePublished":"2021-09-09T12:03:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjYzOSM0Mzk1NTc4IzIwOTU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536233"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536233\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}